Cosentyx Drug Market, By Route of Administration (Subcutaneous injection and Intravenous infusion), By Indication (Hidradenitis suppurativa, Psoriatic arthritis, Ankylosing spondylitis, Plaque Psoriasis, and Others), By Distribution Channel (Hospital Phar

Cosentyx Drug Market, By Route of Administration (Subcutaneous injection and Intravenous infusion), By Indication (Hidradenitis suppurativa, Psoriatic arthritis, Ankylosing spondylitis, Plaque Psoriasis, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Cosentyx (secukinumab) is a human monoclonal antibody that selectively binds and inhibits interleukin-17A (IL-17A), a proinflammatory cytokine that is involved in neutrophil recruitment and activation. Launched in 2015 by Novartis, Cosentyx is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in over 80 countries worldwide. Within the first few years of its launch, it has established itself as one of the top selling drugs, capturing a sizable market share due to its high efficacy and favorable safety profile.

Market Dynamics:

Global cosentyx drug market growth is driven by rising prevalence of immune-mediated inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. Growing awareness about the availability of targeted biologic drugs and their superior efficacy over conventional therapies are driving the market growth. The continuous pipeline expansion through new indications and strengths is expanding the eligible patient pool. However, the drug's patent expiration in major regions by 2027, combined with the market entry of different IL-17 targeting biosimilars, may impede the growth of Cosentyx to some extent. The geographical expansion into emerging markets and development of novel drug delivery systems with improved formulations offer lucrative opportunities for sustained revenues over the long-run.

Key Features of the Study:

• This report provides an in-depth analysis of the global cosentyx drug market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cosentyx drug market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• The key companies covered as a part of this study include Novartis AG.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global cosentyx drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cosentyx drug market.

Detailed Segmentation:

• Route of Administration:
• Subcutaneous injection
• Intravenous infusion
• Indication:
• Hidradenitis suppurativa
• Psoriatic arthritis
• Ankylosing spondylitis
• Plaque Psoriasis
• Others
• Distribution Channel:
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• Novartis AG